BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
路透社2026/10/08 16:11Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Latest Developments
October 8 - ** Pacira BioSciences (PCRX.O) shares surged 44%, hitting a three-year high of 36.30 USD
** If the rally persists, PCRX is set to record its largest single-day gain in history
**Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences for $1.65 billion in cash ((link)), at a price of $36.50 per share
** The offer represents a premium of about 44.8% over Pacira's recent closing price of $25.20
** The deal will add Pacira’s non-opioid pain drugs Exparel and Zilretta to Viatris’ product portfolio
** Viatris shares fell 2.6%, closing at $17.04
** JPMorgan stated: "We believe this acquisition will not markedly alter VTRS’s overall financial profile in the short or long term, and we expect sales of Exparel to gradually decline from 2030 onwards due to the entry of generics."
** Both parties expect the deal to be completed by the end of 2026
**Including intraday volatility, PCRX has risen 40.2% year-to-date, while VTRS has climbed 36.8%
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for readers’ convenience only. Reuters accepts no responsibility for any damage or loss resulting from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Quantum-Si Detects 19 Amino Acids in Proteus Program
05:05 PM EDT, 10/08/2026 (MT Newswires) -- Quantum-Si (QSI) said Thursday it demonstrated detection of 19 amino acids in its Proteus protein sequencing program and is working to deploy the capability into a developmental sequencing kit for routine use on integrated Proteus instruments. The progress follows interim Proteus data presented at the 2026 World HUPO Congress, where a developmental kit detected 18 amino acids. Quantum-Si remains confident in demonstrating detection of all 20 amino acids by year-end and continues to target commercial launch of Proteus in Q2 of 2027, according to the company.
Updated Version 2 - SpaceX Targets U.S. Wireless Operators Through Spectrum Acquisition
Reuters, October 8 – SpaceX reached an agreement on Thursday to acquire a nationwide portfolio of low-frequency spectrum, enabling Elon Musk’s satellite business to mount direct orbital competition against traditional U.S. wireless telecom giants. While Starlink Mobile’s existing global 2 GHz mid-band spectrum will provide high bandwidth capacity, this new spectrum will allow its signals to penetrate obstacles. The financial terms of the deal have not been disclosed. This move accelerates billionaire Musk’s ambitions to bypass traditional wireless infrastructure and provide direct cellular network connections to smartphones from orbit. Low-frequency bands are highly valued in telecommunications for their ability to travel longer distances and penetrate dense structures such as walls and tree cover, thereby overcoming a major technical barrier previously faced by satellite mobile networks. The transaction involves the acquisition of 100% of the nationwide 800 MHz spectrum portfolio held by private equity firm Grain Management and is still subject to regulatory approval from the U.S. Federal Communications Commission (FCC). Telecom stocks fell as investors feared competition from SpaceX could trigger a fierce price war and erode their market share in the already saturated U.S. wireless market. The shares of T-Mobile US, Verizon, and AT&T all dropped more than 5% in after-hours trading. The FCC this week also approved Starlink Mobile’s application for a second-generation satellite constellation, authorizing SpaceX to launch 15,000 satellites worldwide optimized for the 2 GHz band. (For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or may lack required context, Reuters does not guarantee the accuracy of automated translation texts; they are provided solely for readers’ convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
I-On Digital director John Jubilee resigns immediately
John Jubilee resigned from the board of I-On Digital, effective Oct. 5, 2026. Departure was not tied to any dispute over the company’s operations, policies, or practices. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-On Digital Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-046357), on October 08, 2026, and is solely responsible for the information contained therein.
IWF ETF Declines 1.3%
This article was automatically generated using Dow Jones technology. Shares of iShares Russell 1000 Growth ETF dropped 1.3% to $127.11 Thursday on what proved to be an overall negative trading session for the U.S. stock market, with the S&P 500 Index falling 0.5% to 7,765.36. This was the fund's second consecutive day of losses. The fund's underlying index, the Russell 1000 Growth Index, fell 1.3%. The ETF's shares closed 2.1% below the 52-week high of $129.80 seen on October 6, 2026. Trading volume was 4,726,199, compared to the 65-day average trading volume of 3,881,173. As of October 7, the fund's net asset value totaled $128.81 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 08, 2026 16:36 ET (20:36 GMT)